Preoperative Serum Interleukin-6 Is a Potential Prognostic Factor for Colorectal Cancer, including Stage II Patients

Figure 3

Disease-free survival (DFS) rates according to the preoperative serum interleukin-6 (IL-6) status. (a) DFS of all 207 patients who underwent curative resection. (b) DFS of 188 patients with stages I–III colorectal cancer. (c) DFS of the 60 stage II patients.

(a)

(b)

(c)